Search research articles
Contact Us
Filters
Showing results (61-70 of 372) with videos related to
Page
of 38
Sort By:
Gastroenterology
|
December 26, 2021
The Maze of Systemic Therapy for Hepatocellular Carcinoma: Did We Find the Compass?
Alejandro Forner, Massimo Colombo
Gastroenterology
|
July 2, 2015
Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?
Alessio Aghemo, Massimo Colombo
Antiviral Research
|
November 26, 2003
Etiology, natural history and treatment of hepatocellular carcinoma
Massimo Colombo, Angelo Sangiovanni
Gastroenterology
|
October 18, 2019
Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Liver Cancer Risk Reduction: Better Nucleotides than Nucleosides?
Pietro Lampertico, Massimo Colombo
Hepatic Oncology
|
September 8, 2018
Pathway of care of hepatocellular carcinoma in 2017
Federica Invernizzi, Massimo Colombo
Hepatobiliary Surgery and Nutrition
|
May 18, 2019
Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients?
Massimo Colombo, Ana Lleo
Gastroenterology
|
March 1, 2011
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations?
Alessio Aghemo, Massimo Colombo
Gastroenterology
|
November 26, 2009
Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal
Alessio Aghemo, Massimo Colombo
Gastroenterology
|
August 25, 2010
Telaprevir for hepatitis C re-treatment: an open door on a long and winding road
Alessio Aghemo, Massimo Colombo
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 12, 2009
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues
Pietro Lampertico, Massimo Colombo
Page
of 38
Search research articles
Search
Showing results (61-70 of 372) with videos related to
Sort By:
Page
of 38
Gastroenterology
|
December 26, 2021
The Maze of Systemic Therapy for Hepatocellular Carcinoma: Did We Find the Compass?
Alejandro Forner, Massimo Colombo
Gastroenterology
|
July 2, 2015
Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?
Alessio Aghemo, Massimo Colombo
Antiviral Research
|
November 26, 2003
Etiology, natural history and treatment of hepatocellular carcinoma
Massimo Colombo, Angelo Sangiovanni
Gastroenterology
|
October 18, 2019
Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Liver Cancer Risk Reduction: Better Nucleotides than Nucleosides?
Pietro Lampertico, Massimo Colombo
Hepatic Oncology
|
September 8, 2018
Pathway of care of hepatocellular carcinoma in 2017
Federica Invernizzi, Massimo Colombo
Hepatobiliary Surgery and Nutrition
|
May 18, 2019
Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients?
Massimo Colombo, Ana Lleo
Gastroenterology
|
March 1, 2011
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations?
Alessio Aghemo, Massimo Colombo
Gastroenterology
|
November 26, 2009
Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal
Alessio Aghemo, Massimo Colombo
Gastroenterology
|
August 25, 2010
Telaprevir for hepatitis C re-treatment: an open door on a long and winding road
Alessio Aghemo, Massimo Colombo
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 12, 2009
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues
Pietro Lampertico, Massimo Colombo
Page
of 38